Recent years have seen the emergence of noninvasive ventilation (NIV) 
Introduction:
Chronic obstructive pulmonary disease (COPD) is chronic progressive airway disorder characterized by airflow limitation that is not fully reversible or fixed 1 (GOLD 2003) . The airflow limitation is progressive and associated with abnormal inflammatory response to noxious agents, particularly tobacco smoking. The total number of cases of COPD in the world is approximately 280 million persons 2 (Celi et al. 2008) . Moreover the burden of the disease is expected to rise in future. The World Health Organization (WHO) has predicted that by 2020, COPD will be the 5th most prevalent disease worldwide (currently ranked 12th) and will be among the three leading causes of death 3 (Khilnani et al. 2010 ).
Acute exacerbation of COPD (AECOPD) requires hospitalization. Some hospitalised patients, who need endotracheal intubation and mechanical ventilation, frequently develop complications related to endotracheal intubation and ventilation, which increases hospital stay and treatment costs. Endo-tracheal intubation has several hazards such as increased risk of Ventilator Associated Pneumonia (VAP), ulceration of upper airway, haemorrhage and long-term complication such as, tracheal stenosis (Khilnani et al. 2010 ).
Several mechanisms can explain why and how the NIV is beneficial in AECOPD; Noninvasive positive pressure ventilation provides a larger tidal volume with the same inspiratory effort, thus improving alveolar ventilation and decreasing the work of breathing. This treatment can also decrease the work of breathing by partially overcoming auto-positive end-expiratory pressure (auto-PEEP), i.e., pressure remaining in the alveoli at the end of exhalation that is greater than the atmospheric pressure. 
Contraindications:
1) Cardiac or respiratory arrest 2) Non-respiratory organ failure e.g. encephalo-pathy with GCS < 10, severe upper gastrointestinal bleeding and hemodynamic instability 3) Facial trauma, injury and deformity 4) Upper airway obstruction 5) Uncooperative patient 6) Unable to protect airway 7) Unable to clear sputum 8) High risk of aspiration Since SARS, another contraindication for NIPPV in this ICU is all community acquired pneumonias and suspected SARS Case Report:
Mr. Abdul Gani 52 years old male was admitted in our ICU with chief complaints severe breathlessness and sweating for last 5 hours. Before this acute condition he has also history of hardly able to do anything by himself, even taking a bath or getting dressed makes him short of breath since last one year. Previous medical diagnosis was Stage 1 COPD 4 years back and he used to take Ticamet (salmetarol+Fluticasone) he is not diabetic or hypertensive but he suffered from bronchitis with upper respiratory infection for 3 times last year. He was a smoker and used to smoke 1 packet per day for 30 years -has quit 1 year ago. His mother died of cancer colon 3 years back and his father died 2 years back with stroke.
On admission his general appearance was; 52-years-old male in acute respiratory distress using accessory muscles of respiration at rest, which indicate severity of distress. On second day of admission his condition deteriorated: his distress became more pronounced, his work of breathing increased significantly, he became confused, SpO2 went down 80 to 85% with 5L O2/min, a blood gas parameter showed pH; 7.27, PO2: 55, PCO2, 72, Hco3: 30, therefore, with the consent of patient's relatives NIV was added along with the conventional treatment. The NIV was applied as follows:
 Patient was explained about the process.
 Patient kept proptup position to provide effective ventilation and help to prevent aspiration  Noninvasive ventilation started in sitting position with initial settings of IPAP 8 cm H2O and EPAP 4 cm H2O. Gradually IPAP and EPAP were increased 1 cm every 15 minutes up to IPAP 12 cm and EPAP 6cm H2O (best tolerated by this patient). FiO2 was adjusted between 45 to 50% to keep the SpO2 90%.
 Patient was disconnected from ventilator for 10 mines in every 2 hour and only during feeding.
Patient was kept in close monitoring with hourly recording of vital signs, conscious level. Blood gas was measured after 2 hours of administration of NIV and every 6-hour interval.
There was gradual improvement of patient's symptoms and blood gas parameter. After 20 hours of NIV patient's clinical condition significantly improved. Table  2 showed serial recording of vitals and blood gas (Gershman et al. 2008) . Consistent With the previous study our case report also showed NIV has a similar efficacy and benefit when used in selected case of AECOPD. In most of the studies the researchers administered NIV using facial mask. In our study we also have used facial mask but a nasal mask is more patient compliant than a facial mask therefore, we can use nasal mask if available. In most of the successful study it is seen that NIV was administered in ph between 7.25-7.35. In our case study we have applied NIV when patient's PH was 7.27. We tried to keep the patient on NIV as much time as possible to get a good result but we also had to take measures to avoid pressure sores. If there is no improvement of arterial blood gas within first 2 hours and if patient's condition and blood gas parameter deteriorate further we should discontinue NIV and ofcourse think for Intubation and mechanical ventilation. We believe that each and every ICU in Bangladesh can use NIV effectively if only have trained medical staff thereby, can reduce complication related to
Conclusion:
Though only with this single case report we can not determine its efficacy in our clinical setting but On the basis of previous successful controlled trials, we can conclude that administration of NIV in COPD patients who still have good physiological reserve (ph not less than 7.25) can give significant benefit to patient. However, it should not be used as a substitute for intubation and mechanical ventilation if these are needed or if the patient is at risk of aspiration.
